DE3750145T2
(de)
*
|
1986-06-10 |
1994-11-03 |
Euro Celtique Sa |
Zusammensetzung mit kontrollierter Freisetzung von Dihydrocodein.
|
EP0856313A1
(fr)
*
|
1987-10-16 |
1998-08-05 |
ELAN CORPORATION, Plc |
Formulations de diltiazem à absorption contrÔlée
|
AU3432689A
(en)
*
|
1988-03-24 |
1989-10-16 |
Bukh Meditec A/S |
Controlled release composition
|
FR2630913A1
(fr)
*
|
1988-05-09 |
1989-11-10 |
Delalande Sa |
Comprimes de sel(s) hydrosoluble(s) de diltiazem a liberation programmee et leur procede de fabrication
|
CH679373A5
(fr)
*
|
1988-09-20 |
1992-02-14 |
Glaxo Group Ltd |
|
GB9203689D0
(en)
*
|
1992-02-20 |
1992-04-08 |
Euro Celtique Sa |
Pharmaceutical composition
|
JP3623805B2
(ja)
*
|
1992-02-20 |
2005-02-23 |
ユーロセルテイツク・エス・アー |
ヒドロモルホンスフェロイド調整放出製剤
|
US5321012A
(en)
*
|
1993-01-28 |
1994-06-14 |
Virginia Commonwealth University Medical College |
Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
|
USRE39300E1
(en)
|
1993-01-28 |
2006-09-19 |
Virginia Commonwealth University Medical College Of Virginia |
Inhibiting the development of tolerance to and/or dependence on an addictive substance
|
DE4319649A1
(de)
*
|
1993-03-18 |
1994-09-22 |
Asta Medica Ag |
Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
|
IL119660A
(en)
|
1993-05-10 |
2002-09-12 |
Euro Celtique Sa |
Controlled release formulation comprising tramadol
|
US6080428A
(en)
|
1993-09-20 |
2000-06-27 |
Bova; David J. |
Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
|
US6676967B1
(en)
|
1993-09-20 |
2004-01-13 |
Kos Pharmaceuticals, Inc. |
Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
|
US6129930A
(en)
|
1993-09-20 |
2000-10-10 |
Bova; David J. |
Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
|
US6818229B1
(en)
|
1993-09-20 |
2004-11-16 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia
|
US20060263428A1
(en)
*
|
1993-09-20 |
2006-11-23 |
Eugenio Cefali |
Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
|
US6746691B2
(en)
|
1993-09-20 |
2004-06-08 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
|
WO1995013798A1
(fr)
*
|
1993-11-18 |
1995-05-26 |
Cancer Research Institute Inc. |
Preparation a liberation regulee
|
US5891471A
(en)
*
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
KR100354702B1
(ko)
*
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
US5419917A
(en)
*
|
1994-02-14 |
1995-05-30 |
Andrx Pharmaceuticals, Inc. |
Controlled release hydrogel formulation
|
US5843480A
(en)
*
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
GB9422154D0
(en)
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US5931809A
(en)
|
1995-07-14 |
1999-08-03 |
Depotech Corporation |
Epidural administration of therapeutic compounds with sustained rate of release
|
CA2251008C
(fr)
*
|
1996-04-05 |
2007-11-13 |
The Board Of Trustees Of The University Of Illinois |
Complexes macromoleculaires pour administration de medicaments
|
US6057367A
(en)
|
1996-08-30 |
2000-05-02 |
Duke University |
Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
|
US5935599A
(en)
*
|
1996-10-28 |
1999-08-10 |
The Board Of Trustees Of The University Of Illinois |
Polymer-associated liposomes for drug delivery and method of manufacturing the same
|
JP2001526229A
(ja)
*
|
1997-12-22 |
2001-12-18 |
ユーロ−セルティーク,エス.エイ. |
オピオイド投薬剤形の乱用を防止する方法
|
ES2412409T3
(es)
|
1997-12-22 |
2013-07-11 |
Euro-Celtique S.A. |
Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
|
US6524620B2
(en)
|
1998-07-20 |
2003-02-25 |
Andrx Pharmaceuticals, Inc. |
Diltiazem controlled release formulation and method of manufacture
|
US6248363B1
(en)
*
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
US20030236236A1
(en)
*
|
1999-06-30 |
2003-12-25 |
Feng-Jing Chen |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
US20060034937A1
(en)
*
|
1999-11-23 |
2006-02-16 |
Mahesh Patel |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
US6821995B1
(en)
|
1999-12-01 |
2004-11-23 |
Duke University |
Method of treating batten disease
|
GEP20053614B
(en)
|
2000-02-08 |
2005-09-26 |
Euro Celtique Sa |
Compositions for Oral Administration Containing Opioid Agonist
|
US6635277B2
(en)
|
2000-04-12 |
2003-10-21 |
Wockhardt Limited |
Composition for pulsatile delivery of diltiazem and process of manufacture
|
US6955821B2
(en)
*
|
2000-04-28 |
2005-10-18 |
Adams Laboratories, Inc. |
Sustained release formulations of guaifenesin and additional drug ingredients
|
US7985420B2
(en)
*
|
2000-04-28 |
2011-07-26 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
US8012504B2
(en)
*
|
2000-04-28 |
2011-09-06 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
US7838032B2
(en)
*
|
2000-04-28 |
2010-11-23 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin
|
US6417237B1
(en)
*
|
2000-06-08 |
2002-07-09 |
The Board Of Trustees Of The University Of Illinois |
Macromolecular drug complexes and compositions containing the same
|
DE10031043A1
(de)
*
|
2000-06-26 |
2002-02-14 |
Bayer Ag |
Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
|
US6855721B1
(en)
|
2000-07-28 |
2005-02-15 |
Indevus Pharmaceuticals, Inc. |
Methods and compositions for alleviating stuttering
|
CA2446550C
(fr)
|
2001-05-11 |
2012-03-06 |
Endo Pharmaceuticals, Inc. |
Forme posologique d'opioides a liberation prolongee empechant la consommation abusive
|
WO2003007802A2
(fr)
*
|
2001-07-18 |
2003-01-30 |
Euro-Celtique, S.A. |
Combinaisons pharmaceutiques d'oxycodone et naloxone
|
AU2002323032B2
(en)
|
2001-08-06 |
2005-02-24 |
Euro-Celtique S.A. |
Opioid agonist formulations with releasable and sequestered antagonist
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
WO2003013433A2
(fr)
*
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Formulations d'antagoniste sequestre
|
CA2708900C
(fr)
|
2002-04-05 |
2019-06-04 |
Purdue Pharma |
Preparation pharmaceutique contenant oxycodone et naloxone
|
AU2003272601B2
(en)
*
|
2002-09-20 |
2009-05-07 |
Alpharma Pharmaceuticals, Llc |
Sustained-release opioid formulations and methods of use
|
DK1551372T3
(en)
*
|
2002-09-20 |
2018-07-23 |
Alpharma Pharmaceuticals Llc |
SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
|
US20040192781A1
(en)
*
|
2003-03-31 |
2004-09-30 |
Haley Eugene T. |
Method of administration for metoclopramide and pharmaceutical formulation therefor
|
US20050137265A1
(en)
*
|
2003-03-31 |
2005-06-23 |
Haley Eugene T. |
Rapidly dissolving metoclopramide solid oral dosage and method thereof
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
US8906413B2
(en)
|
2003-05-12 |
2014-12-09 |
Supernus Pharmaceuticals, Inc. |
Drug formulations having reduced abuse potential
|
US20060003002A1
(en)
*
|
2003-11-03 |
2006-01-05 |
Lipocine, Inc. |
Pharmaceutical compositions with synchronized solubilizer release
|
US20070196413A1
(en)
*
|
2003-12-18 |
2007-08-23 |
Huntsman Petrochemical Corporation |
Surfactant enhanced quick release pesticide granules
|
RU2388466C2
(ru)
*
|
2004-04-27 |
2010-05-10 |
Медисинова, Инк. |
Производные феноксиалкилкарбоновых кислот при лечении воспалительных заболеваний
|
KR100753984B1
(ko)
*
|
2004-05-14 |
2007-08-31 |
강원대학교산학협력단 |
우회전성 모르피난의 신경보호적 특성
|
EP1604666A1
(fr)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioides pour le traitement de la bronchopneumopathie chronique obstructive
|
ES2531735T3
(es)
*
|
2004-10-15 |
2015-03-18 |
Supernus Pharmaceuticals, Inc. |
Preparaciones farmacéuticas con menor potencial de abuso
|
EP1702558A1
(fr)
*
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Procédé et dispositif pour évaluer la fonction de l'activité intestinale
|
EP1879583A2
(fr)
*
|
2005-05-03 |
2008-01-23 |
Mutual Pharmaceutical Company, Inc. |
Preparations de quinine
|
CN101299993A
(zh)
*
|
2005-11-04 |
2008-11-05 |
伊士曼化工公司 |
用于给药难溶的药学活性剂的羧烷基纤维素酯
|
US20070190141A1
(en)
*
|
2006-02-16 |
2007-08-16 |
Aaron Dely |
Extended release opiate composition
|
EP2526932B1
(fr)
*
|
2006-06-19 |
2017-06-07 |
Alpharma Pharmaceuticals LLC |
Composition pharmaceutique
|
US20080279930A1
(en)
*
|
2007-05-07 |
2008-11-13 |
Bernd Terhaag |
Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US20100003322A1
(en)
*
|
2008-07-03 |
2010-01-07 |
Lai Felix S |
Enteric coated hydrophobic matrix formulation
|
PE20110422A1
(es)
*
|
2008-07-07 |
2011-07-01 |
Euro Celtique Sa |
Composicion farmaceutica que comprende antagonistas opioides
|
WO2010078486A2
(fr)
|
2008-12-31 |
2010-07-08 |
Upsher-Smith Laboratories, Inc. |
Compositions pharmaceutiques orales contenant un opioïde et procédés
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
PT2405915T
(pt)
|
2009-03-10 |
2019-01-29 |
Euro Celtique Sa |
Composições farmacêuticas de libertação imediata compreendendo oxicodona e naloxona
|
CA2773521C
(fr)
|
2009-09-17 |
2017-01-24 |
Upsher-Smith Laboratories, Inc. |
Produit a liberation prolongee comprenant une combinaison d'une amine non opioide et d'un medicament anti-inflammatoire non steroidal
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US9034858B2
(en)
|
2010-11-30 |
2015-05-19 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US9358241B2
(en)
|
2010-11-30 |
2016-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
JP2013119550A
(ja)
|
2011-12-08 |
2013-06-17 |
Medicinova Inc |
非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の処置方法
|
US8962687B2
(en)
|
2012-12-05 |
2015-02-24 |
Medicinova, Inc. |
Method of treating liver disorders
|
EP3024461B1
(fr)
|
2013-07-23 |
2020-05-13 |
Euro-Celtique S.A. |
Combinaison d'oxycodone et de la naloxone pour utilisation dans le traitement de la douleur chez des patients souffrant de douleurs et d'une maladie résultant de dysbioses intestinales et/ou augmentant le risque de la la translocation bacterienne
|
CA2917780C
(fr)
|
2013-07-25 |
2023-01-24 |
Medicinova, Inc. |
Procedes pour reduire les niveaux de sang de triglyceride, de cholesterol total et de lipoproteine de basse densite
|
WO2015088990A1
(fr)
|
2013-12-09 |
2015-06-18 |
Durect Corporation |
Complexes de principes pharmaceutiquement actifs, complexes de polymères, et compositions et procédés les impliquant
|
US9346754B2
(en)
|
2014-05-08 |
2016-05-24 |
Medicinova, Inc. |
Method of treating advanced non-alcoholic steatohepatitis
|
US20150321989A1
(en)
|
2014-05-08 |
2015-11-12 |
Medicinova, Inc. |
Method of treating idiopathic pulmonary fibrosis
|
ES2957213T3
(es)
|
2014-06-02 |
2024-01-15 |
Medicinova Inc |
Método para inhibir o tratar la fibrosis
|
WO2016033549A2
(fr)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
Compositions de (17-ss)-3-oxoandrost-4-èn-17-yl tridécanoate et leurs procédés de préparation et d'utilisation
|
US9498485B2
(en)
|
2014-08-28 |
2016-11-22 |
Lipocine Inc. |
Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
|
KR102462638B1
(ko)
|
2014-11-26 |
2022-11-03 |
메디시노바, 인크. |
이부딜라스트와 릴루졸의 배합물 및 이의 사용방법
|
WO2017062997A1
(fr)
|
2015-10-09 |
2017-04-13 |
Reckitt Benckiser Llc |
Formulation pharmaceutique
|
US20180147215A1
(en)
|
2016-11-28 |
2018-05-31 |
Lipocine Inc. |
Oral testosterone undecanoate therapy
|
EP4346783A1
(fr)
|
2021-05-28 |
2024-04-10 |
MediciNova, Inc. |
Dérivés d'acide phénoxyalkylcarboxylique et leur utilisation pour abaisser les taux de triglycérides
|